Cristobal Goa, MD
Cardiovascular Disease · Fairfax, VANPI 1528201993
Payments from drug & device makers
Across 298 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Johnson & Johnson$833
- Novartis$467
- E.r. Squibb & Sons, L.L.C.$333
- Amgen$326
- GSK$292
- plus $3K from 34 others
What the payments were for
- Consulting fees$1,08118%
- Speaking & faculty fees$1252%
- Food & beverage$4,78880%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 2 | $1,081 |
| Johnson & Johnson(3 entities) | 70 | $833 |
| Novartis | 21 | $467 |
| E.r. Squibb & Sons, L.L.C. | 18 | $333 |
| Amgen(2 entities) | 22 | $326 |
| GSK | 24 | $292 |
| Merck | 12 | $269 |
| Pfizer | 9 | $199 |
| Sanofi | 6 | $196 |
| Actelion Pharmaceuticals US, Inc. | 11 | $186 |
| Boston Scientific | 11 | $180 |
| Abbott | 3 | $159 |
| Boehringer Ingelheim | 8 | $154 |
| Esperion Therapeutics, Inc. | 7 | $149 |
| Jazz Pharmaceuticals Inc. | 8 | $121 |
| Sanofi-aventis U.S. LLC | 6 | $118 |
| UCB, Inc. | 7 | $95 |
| Novo Nordisk | 3 | $91 |
| Insmed, Inc. | 6 | $85 |
| AstraZeneca | 4 | $73 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $73 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $66 |
| Scpharmaceuticals Inc. | 3 | $51 |
| Harmony Biosciences LLC | 4 | $49 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $40 |
| Sanofi US Services Inc. | 1 | $36 |
| Heartflow, Inc. | 2 | $32 |
| United Therapeutics Corporation | 2 | $29 |
| Octapharma USA, Inc. | 2 | $28 |
| Gilead | 2 | $28 |
| Lilly USA, LLC | 2 | $24 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $16 |
| Sobi, Inc | 1 | $15 |
| Circassia Inc. | 1 | $14 |
| AbbVie | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Janssen Scientific Affairs, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,018 in reported general payments places this provider in the 70th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 106 | $150,262 |
| XareltoRivaroxaban | 37 | $44,813 |
| EntrestoSacubitril/Valsartan | 35 | $43,411 |
| JardianceEmpagliflozin | 17 | $20,421 |
| Metoprolol Succinate | 184 | $2,596 |
| Rosuvastatin Calcium | 119 | $2,013 |
| Valsartan | 44 | $2,007 |
| Ezetimibe | 59 | $1,925 |
| Atorvastatin Calcium | 187 | $1,843 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 24 | $930 |
| Bisoprolol Fumarate | 39 | $844 |
| Carvedilol | 75 | $799 |
| Spironolactone | 67 | $748 |
| Losartan Potassium | 112 | $724 |
| Nifedipine ErNifedipine | 17 | $630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $199 | $150,262106 claims |
| Johnson & JohnsonXarelto | $833 | $44,81337 claims |
| NovartisEntresto | $467 | $43,41135 claims |
| Boehringer IngelheimJardiance | $154 | $20,42117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Fairfax
- David KopinFairfax$386K
- Jared SpitzFairfax$303K
- Constantine TzirosFairfax$250K
- Eunice YangFairfax$135K
- Tariq HaddadFalls Church$8M
- David LimCharlottesville$6M
- Hamid TaheriManassas$4.9M
- Philip OdonnellWinchester$4.6M
- Antonio AbbateCharlottesville$4M
- George VetrovecRichmond$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.